Published in Mol Cell Endocrinol on January 27, 2006
CASK interacts with PMCA4b and JAM-A on the mouse sperm flagellum to regulate Ca2+ homeostasis and motility. J Cell Physiol (2012) 0.94
Plasma membrane Ca2+-ATPase 4 in murine epididymis: secretion of splice variants in the luminal fluid and a role in sperm maturation. Biol Reprod (2013) 0.87
Switch of PMCA4 splice variants in bovine epididymis results in altered isoform expression during functional sperm maturation. J Biol Chem (2010) 0.85
Expression and localization of PMCA4 in rat testis and epididymis. Histochem Cell Biol (2007) 0.81
State-of-the-art technologies, current opinions and developments, and novel findings: news from the field of histochemistry and cell biology. Histochem Cell Biol (2008) 0.75
Amarcord: I remember. J Biol Chem (2013) 0.75
Genome-wide profiling of gene expression in the epididymis of alpha-chlorohydrin-induced infertile rats using an oligonucleotide microarray. Reprod Biol Endocrinol (2010) 0.75
Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart (2011) 2.87
A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol (2013) 2.04
Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol (2008) 2.01
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension (2007) 1.68
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res (2005) 1.66
Atrial fibrillation is under-recognized in chronic heart failure: insights from a heart failure cohort treated with cardiac resynchronization therapy. Europace (2009) 1.62
Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice? JACC Cardiovasc Interv (2013) 1.58
The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol (2010) 1.58
Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics (2011) 1.57
Use of the sheathless guide catheter during routine transradial percutaneous coronary intervention: a feasibility study. Catheter Cardiovasc Interv (2010) 1.53
Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. Cardiovasc Res (2010) 1.51
Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol (2005) 1.51
What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies. Heart Fail Rev (2012) 1.49
Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension (2006) 1.49
Calcineurin in human heart hypertrophy. Circulation (2002) 1.47
The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail (2010) 1.43
Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition. J Hypertens (2002) 1.42
The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem (2006) 1.41
A comparison of drug-eluting stents versus bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis. J Interv Cardiol (2011) 1.38
Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility. J Biol Chem (2004) 1.37
Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet (2006) 1.30
Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation (2007) 1.27
A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail (2009) 1.24
Targeted proteolysis sustains calcineurin activation. Circulation (2005) 1.21
Interaction of the plasma membrane Ca2+ pump 4b/CI with the Ca2+/calmodulin-dependent membrane-associated kinase CASK. J Biol Chem (2003) 1.19
Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation (2011) 1.18
Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation (2005) 1.17
The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit. J Biol Chem (2005) 1.14
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem (2004) 1.12
Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ Res (2009) 1.11
Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res (2007) 1.10
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol (2011) 1.10
Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res (2010) 1.06
Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res (2007) 1.06
Resting Pd/Pa measured with intracoronary pressure wire strongly predicts fractional flow reserve. J Invasive Cardiol (2010) 0.99
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail (2010) 0.98
Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium. J Biol Chem (2009) 0.96
Inhibition of nuclear import of calcineurin prevents myocardial hypertrophy. Circ Res (2006) 0.96
Minimising radial injury: prevention is better than cure. EuroIntervention (2014) 0.96
Regulation of vascular tone in animals overexpressing the sarcolemmal calcium pump. J Biol Chem (2003) 0.95
Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension (2003) 0.94
Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem (2011) 0.93
Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation (2009) 0.92
What can we learn from patients with heart failure about exercise adherence? A systematic review of qualitative papers. Health Psychol (2011) 0.92
The interaction between endogenous calcineurin and the plasma membrane calcium-dependent ATPase is isoform specific in breast cancer cells. FEBS Lett (2007) 0.92
Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail (2013) 0.91
A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail (2013) 0.91
AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J (2002) 0.90
Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats. Biochem Biophys Res Commun (2005) 0.89
Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps. Sci China Life Sci (2011) 0.89
Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis (2011) 0.87
Late outcomes of drug eluting and bare metal stents in saphenous vein graft percutaneous coronary intervention. EuroIntervention (2011) 0.87
Physiological implications of the interaction between the plasma membrane calcium pump and nNOS. Pflugers Arch (2008) 0.86
Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol (2013) 0.86
What influences physical activity in people with heart failure?: a qualitative study. Int J Nurs Stud (2011) 0.86
The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med (2003) 0.86
Rational promoter selection for gene transfer into cardiac cells. J Mol Cell Cardiol (2003) 0.84
Plasma membrane calcium ATPase and its relationship to nitric oxide signaling in the heart. Ann N Y Acad Sci (2007) 0.84
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol (2002) 0.84
The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res (2009) 0.84
Development and characterization of a novel fluorescent indicator protein PMCA4-GCaMP2 in cardiomyocytes. J Mol Cell Cardiol (2013) 0.83
Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. Carcinogenesis (2012) 0.83
Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension (2006) 0.82
Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload. J Mol Cell Cardiol (2011) 0.82
The emergence of plasma membrane calcium pump as a novel therapeutic target for heart disease. Mini Rev Med Chem (2006) 0.82
Local signals with global impacts and clinical implications: lessons from the plasma membrane calcium pump (PMCA4). Biochim Biophys Acta (2010) 0.82
Calcium transport in cardiovascular health and disease--the sarcolemmal calcium pump enters the stage. J Mol Cell Cardiol (2005) 0.82
Plasma membrane calcium ATPase proteins as novel regulators of signal transduction pathways. World J Biol Chem (2010) 0.81
Estrogen receptor alpha interacts with 17beta-hydroxysteroid dehydrogenase type 10 in mitochondria. Biochem Biophys Res Commun (2009) 0.81
Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age. J Am Heart Assoc (2014) 0.81
Optimization of gene transfer into neonatal rat cardiomyocytes and unmasking of cytomegalovirus promoter silencing. DNA Cell Biol (2005) 0.79
Calcium signaling dysfunction in heart disease. Biofactors (2011) 0.79
Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit Rev Clin Lab Sci (2013) 0.78
What are the thromboembolic risks of heart failure combined with chronic or paroxysmal AF? J Card Fail (2010) 0.78
Mitogen-activated protein kinase kinase 4 deficiency in cardiomyocytes causes connexin 43 reduction and couples hypertrophic signals to ventricular arrhythmogenesis. J Biol Chem (2011) 0.78
Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodelling in mitral valve prolapse patients. Eur J Heart Fail (2007) 0.78
Circulating Histone Concentrations Differentially Affect the Predominance of Left or Right Ventricular Dysfunction in Critical Illness. Crit Care Med (2016) 0.78
A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol (2010) 0.77